Use of tamoxifen by young women is influenced by fertility concerns
The risk of breast cancer recurrence and mortality is decreased by endocrine therapy (ET) such as tamoxifen, but younger patients may decline it or discontinue treatment early if they are concerned about fertility, according to a study published August 24 in the JNCI: Journal of the National Cancer Institute.
To explore the reasons for lower initiation and continuation with tamoxifen treatment by younger women with breast cancer, Jacqueline S. Jeruss M.D., Ph.D. of The University of Michigan School of Medicine, Ann Arbor, MI and colleagues conducted a study of 515 premenopausal ...





